Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biomarin Pharmaceuticals (BMRN)

Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,359,306
  • Shares Outstanding, K 190,583
  • Annual Sales, $ 2,419 M
  • Annual Income, $ 167,650 K
  • EBIT $ 386 M
  • EBITDA $ 481 M
  • 60-Month Beta 0.28
  • Price/Sales 4.54
  • Price/Cash Flow 36.01
  • Price/Book 2.27

Options Overview Details

View History
  • Implied Volatility 40.60% ( +1.15%)
  • Historical Volatility 25.82%
  • IV Percentile 97%
  • IV Rank 69.75%
  • IV High 48.42% on 08/05/24
  • IV Low 22.57% on 04/26/24
  • Put/Call Vol Ratio 0.24
  • Today's Volume 226
  • Volume Avg (30-Day) 1,404
  • Put/Call OI Ratio 0.98
  • Today's Open Interest 44,854
  • Open Int (30-Day) 40,977

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.55
  • Number of Estimates 11
  • High Estimate 0.63
  • Low Estimate 0.49
  • Prior Year 0.26
  • Growth Rate Est. (year over year) +111.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.63 +6.96%
on 01/16/25
65.95 -1.67%
on 02/13/25
+1.04 (+1.63%)
since 01/14/25
3-Month
60.63 +6.96%
on 01/16/25
69.70 -6.96%
on 01/08/25
-0.75 (-1.14%)
since 11/14/24
52-Week
60.63 +6.96%
on 01/16/25
94.85 -31.63%
on 08/20/24
-21.16 (-24.60%)
since 02/14/24

Most Recent Stories

More News
BMY Q4 Earnings and Sales Beat Estimates, Shares Down on 2025 Outlook

Bristol-Myers Squibb Company BMY reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.67, which beat the Zacks Consensus Estimate of $1.46.  In the year-ago quarter, BMY posted an adjusted...

ALNY : 256.45 (-3.19%)
BMRN : 64.85 (+0.67%)
PFE : 25.53 (-0.43%)
BMY : 53.90 (-3.70%)
Will Non-COVID Drugs Drive PFE's Top Line in Q4 Earnings?

Pfizer’s PFE non-COVID operational revenues improved in the first three quarters of 2024, driven by its key in-line products like Vyndaqel and Eliquis, new launches like Abrysvo and newly acquired products...

ALNY : 256.45 (-3.19%)
BMRN : 64.85 (+0.67%)
PFE : 25.53 (-0.43%)
BNTX : 119.83 (-2.40%)
Novartis Posts Q4 Earnings and Sales Beat, Shares Gain

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the fourth quarter of 2024. Core earnings (excluding one-time charges) of $1.98 per share easily beat the Zacks Consensus Estimate...

ALNY : 256.45 (-3.19%)
BMRN : 64.85 (+0.67%)
NVS : 105.43 (-2.12%)
RHHBY : 41.0500 (-0.58%)
10 Magnificent Stocks That Can Make You Richer in 2025

A new year brings with it new opportunities to grow your wealth on Wall Street.

BABA : 124.73 (+4.34%)
COMP : 7.93 (+4.62%)
META : 736.67 (+1.11%)
FVRR : 33.36 (+1.58%)
S : 24.80 (-0.68%)
V : 353.81 (-0.51%)
BMRN : 64.85 (+0.67%)
PINS : 38.87 (-0.56%)
PFE : 25.53 (-0.43%)
O : 54.49 (-0.78%)
NEE : 68.06 (-0.79%)
Is Incyte Stock Outperforming the Dow?

Incyte has outperformed the Dow recently, and analysts remain moderately optimistic about the stock’s prospects.

BMRN : 64.85 (+0.67%)
INCY : 70.42 (+0.59%)
$DOWI : 44,546.08 (-0.37%)
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical (BMRN) Stock?

Investors in BioMarin Pharmaceutical Inc. BMRN need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2025 $40 Call had some of the highest implied...

BMRN : 64.85 (+0.67%)
Can BioMarin Stock Live Up to Wall Street’s High Expectations?

BioMarin has greatly improved the fundamentals of its business, but continues losing value. Is the tide ready to turn, or is more of the same on the horizon?

ASND : 144.08 (+1.12%)
BMRN : 64.85 (+0.67%)
Implied Volatility Surging for BioMarin Pharmaceutical (BMRN) Stock Options

Investors in BioMarin Pharmaceutical Inc. BMRN need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2025 $40.00 Call had some of the highest...

BMRN : 64.85 (+0.67%)
BioMarin: Q3 Earnings Snapshot

BioMarin: Q3 Earnings Snapshot

BMRN : 64.85 (+0.67%)
2 'Strong Buy'-Rated Stocks That Could Rally 39% to 48% in 2025

Both of these growth stocks are positioned for long-term success.

NVDA : 138.85 (+2.63%)
$NASX : 20,026.77 (+0.41%)
$SPX : 6,114.63 (-0.01%)
MU : 99.52 (+4.04%)
BMRN : 64.85 (+0.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder),...

See More

Key Turning Points

3rd Resistance Point 67.62
2nd Resistance Point 66.54
1st Resistance Point 65.70
Last Price 64.85
1st Support Level 63.78
2nd Support Level 62.70
3rd Support Level 61.86

See More

52-Week High 94.85
Fibonacci 61.8% 81.78
Fibonacci 50% 77.74
Fibonacci 38.2% 73.70
Last Price 64.85
52-Week Low 60.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar